Dalteparin Sodium | ||||
Source | Intestinal mucosa of pigs | |||
Quality standard |
USP |
EP |
||
characters |
Appearance |
/ |
white or almost white; hygroscopic powder | |
solubility |
/ |
freely soluble in water | ||
identification |
1H NMR SPECTRUM :The ppm values for the methyl group of N-acetyl, the H-2 of N-sulfo glucosamine, the H-2 of glucuronic acid plus 3-O-sulfo glucosamine, the H-1 of iduronic acid, the H-1 of the 2-O-sulfo iduronic acid linked to the terminal anhydromannitol and the H-1 of 2-O-sulfo iduronic acid, and the H-1 of 3-O-sulfo glucosamine of dalteparin in the Sample solution are present at 2.05, 3.28, 3.39, 5.01, 5.18–5.22, and 5.51, respectively. The ppm values of these signals do not differ by more than ±0.03 ppm. |
The 13C NMR spectrum obtained is similar to that obtained with the appropriate specific dalteparin sodium CRS |
||
Mw : 5600 -6400Da, M≤3000 : NMT 13.0%,M≥8000:15.0%-25.0% |
Mw : 5600 -6400Da, M≤3000 : NMT 13.0%,M≥8000:15.0%-25.0% |
|||
Anti-factor Xa activity/ anti- factor IIa : 1.9-3.2 |
Anti- factor Xa activity/ anti- factor IIa : 1.9-3.2 |
|||
It complies with the test for sodium |
It complies with the test for sodium | |||
Appearance of solution | / |
The solution is clear (2.2.1) and not more intensely coloured than intensity 5 of the range of reference solutions of the most appropriate colour (2.2.2, Method II). |
||
pH |
5.5-8.0 |
5.5-8.0 |
||
Molar ratio of Sulfate carboxylate | ≥1.8 | ≥ 1.8 | ||
Nitrogen |
1.5 %-2.5 % (on the dried basis) |
1.5 %-2.5 % (on the dried basis) |
||
Sodium | 10.5% -13.5% (on the dried basis) |
10.5% -13.5% (on the dried basis) |
||
Nitrite |
≤ 5ppm |
≤ 5ppm |
||
Loss on drying |
≤10.0% |
≤5.0% |
||
Bacterial endotoxins |
<0.01EU/U |
<0.01EU/IU |
||
Boron |
≤1ppm |
≤ 1ppm |
||
Assay | Anti- factor Xa activity |
110-210 IU/mg (on the dried basis) |
110-210 IU/mg (on the dried basis) |
|
Anti- factor IIa activity |
35-100 IU/mg (on the dried basis) |
35-100 IU/mg (on the dried basis) |
Treat acute deep vein thrombosis.
Prevent coagulation in the extracorporeal circulation system during hemodialysis and blood filtration in patients with acute renal failure or chronic renal insufficiency.
Treat unstable coronary artery diseases, such as unstable angina and non Q-wave myocardial infarction.
Prevent thrombosis related to surgery.